The objective of this observational study is to compare the differences in proteomics and gut microbiome between the liver cirrhosis group without hepatic encephalopathy and the hepatic encephalopathy group through proteomics and microbiome analysis, screen out the characteristic proteomics and microbiome of patients with hepatic encephalopathy, guide clinical diagnosis and treatment, and conduct in-depth research on the pathogenesis of hepatic encephalopathy. The main questions it aims to answer are:
Are there any differences in serum proteomes between patients with liver cirrhosis without hepatic encephalopathy and those with hepatic encephalopathy? If so, what are the main protein differences? There are differences in the fecal microbiome between patients with liver cirrhosis without hepatic encephalopathy and those with hepatic encephalopathy? If so, what are the main microbial differences?
This study will screen for the differences in proteomes and gut microbiomes between patients with liver cirrhosis without hepatic encephalopathy and those with hepatic encephalopathy, and identify the characteristic proteomes and microbiomes of patients with hepatic encephalopathy to guide clinical diagnosis and treatment.
Aged between 18 and 85 years, inclusive.
Diagnosis of liver cirrhosis.
Normal blood ammonia level.
West-Haven Criteria grade 0 for Hepatic Encephalopathy.
Diagnosis of any malignant tumor.
History of treatment for any malignant tumor.
Presence of severe concomitant cardiac, pulmonary, cerebral, or renal diseases, or severe diabetic complications.
Use of antibiotics, prebiotics, probiotics, or proton pump inhibitors within the three months prior to enrollment.